Our results showed that CTCs were detected in 35.71% (5/14) of pancreatic cancer patients with stromal Cav-1 expression versus 77.42% (24/31) of patients with stromal Cav-1 loss (Fig. 5). This evidence concerns the gene CAV1 and familial pancreatic carcinoma.